Last reviewed · How we verify

NCT03586063

Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis

Completed Last updated 13 July 2018
What this trial tests

trial testing Data collection in Internal Endometriosis in 465 participants. Completed in 24 December 2014.

Timeline
3 November 2011
Primary endpoint
24 December 2014
24 December 2014

Quick facts

Lead sponsorIpsen
StatusCompleted
Study typeOBSERVATIONAL
Enrollment465
Start date3 November 2011
Primary completion24 December 2014
Estimated completion24 December 2014
Sites34 locations across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Ipsen — full company profile →

Who can join

Adults 25 to 40, female only, with Internal Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To describe Gonadotropin-Releasing Hormone agonists (GnRH-a) treatment effectiveness on reduction of internal genital endometriosis symptom - menorrhagia - in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3,75 mg - assessment performed six months after the last injection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other Ipsen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03586063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing